Recombinant human interleukin-1–receptor antagonist is modestly effective in rheumatoid arthritis, 5 whereas its remarkable effect in the Muckle–Wells syndrome supports in vitro findings 2 ...

The Role of the Interleukin-1–Receptor Antagonist in Blocking Inflammation Mediated by Interleukin-1 Author : Charles A. Dinarello , M.D. Author Info & Affiliations Published September 7, 2000 ...

A multicenter, double-blind, dose ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression ...

Researchers described the detection of a human interleukin-1β antagonist with low molecular weight that disrupts interactions with the interleukin-1 receptor type I receptor.

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

The study’s secondary endpoints include expression levels of interleukin-1 receptor antagonist (IL-1Ra) in synovial fluid at Month 12, as well as change from baseline to Month 12.

Objectives Achilles tendinopathy (AT) is a multifactorial condition for which genetic risk factors have been identified. A pathway-based approach was used to investigate genes within the inflammatory ...

During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...

SAN DIEGO -- Patients with moderate to severe ulcerative colitis experienced clinical, endoscopic, histological, and biological improvements with the first-in-class interleukin (IL)-7 receptor ...

Amylyx Pharmaceuticals Inc. has entered into a collaboration with Gubra A/S to develop a novel long-acting GLP-1 receptor antagonist.

IL-1ra is a competitive antagonist of IL-1R1 that selectively binds, but fails to trigger receptor association with the accessory protein resulting in blockade of all known actions of IL-1. A ...